The dynamics of QuantiFERON-TB Gold in-Tube conversion and reversion in a cohort of South African adolescents

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 5, 2015, Pages 584-591

  Andrews, Jason R ^a   Hatherill, Mark ^b,c   Mahomed, Hassan ^d,e   Hanekom, Willem A ^b,c   Campo, Monica ^f   Hawn, Thomas R ^f   Wood, Robin ^c   Scriba, Thomas J ^b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d WESTERN CAPE DEPARTMENT OF AGRICULTURE   (South Africa)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescents; Epidemiology; Interferon release assays; Tuberculin skin tests; Tuberculosis

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS TEST KIT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOUTH AFRICAN; TUBERCULIN TEST; TUBERCULOSIS; DIAGNOSTIC KIT; ISOLATION AND PURIFICATION; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES; SOUTH AFRICA; TUBERCULOSIS, PULMONARY;

DIAGNOSTIC KIT; GAMMA INTERFERON;

ADOLESCENT; CHILD; HUMANS; INTERFERON-GAMMA; MYCOBACTERIUM TUBERCULOSIS; REAGENT KITS, DIAGNOSTIC; SOUTH AFRICA; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY;

EID: 84923130757     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201409-1704OC     Document Type: Article

References (43)

1. Machingaidze S, Verver S, Mulenga H, Abrahams DA, Hatherill M, Hanekom W, Hussey GD, Mahomed H. Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents. Am J Respir Crit Care Med 2012;186:1051-1056.
2. Mahomed H, Hawkridge T, Verver S, Abrahams D, Geiter L, Hatherill M, Ehrlich R, Hanekom WA, Hussey GD. The tuberculin skin test versus QuantiFERON TB Gold® in predicting tuberculosis disease in an adolescent cohort study in South Africa. PLoS One 2011;6:e17984.
3. Mahomed H, Hawkridge T, Verver S, Geiter L, Hatherill M, Abrahams DA, Ehrlich R, Hanekom WA, Hussey GD; SATVI Adolescent Study Team. Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa. Int J Tuberc Lung Dis 2011;15:331-336.
4. Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, Metcalfe JZ, Cattamanchi A, Dowdy DW, Dheda K, et al . Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 2014;27:3-20.
5. ClinicalTrials.gov. A randomized, placebo controlled, partially blinded phase II study to evaluate safety, immunogenicity, and prevention of infection with Mycobacterium tuberculosis of AERAS-404 and BCG revaccination in healthy adolescents (040-404) [accessed 2014 Apr 30]. Available from: http://clinicaltrials.gov/ct2/show/NCT02075203.
6. van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, Badri M, Zumla A, Sechi LA, Bateman ED, et al. Within-subject variability and boosting of T-cell interferon-γ responses after tuberculin skin testing. Am J Respir Crit Care Med 2009;180:49-58.
7. Veerapathran A, Joshi R, Goswami K, Dogra S, Moodie EE, Reddy MV, Kalantri S, Schwartzman K, Behr MA, Menzies D, et al. T-cell assays for tuberculosis infection: deriving cut-offs for conversions using reproducibility data. PLoS One 2008;3:e1850.
8. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Kalantri S, Reingold AL, Colford JM Jr, Riley LW, Menzies D. Serial testing of health care workers for tuberculosis using interferon-γ assay. Am J Respir Crit Care Med 2006;174:349-355.
9. Zwerling A, Cojocariu M, McIntosh F, Pietrangelo F, Behr MA, Schwartzman K, Benedetti A, Dendukuri N, Menzies D, Pai M. TB screening in Canadian health care workers using interferon-γ release assays. PLoS One 2012;7:e43014.
10. Gaur RL, Pai M, Banaei N. Impact of blood volume, tube shaking, and incubation time on reproducibility of QuantiFERON-TB Gold In-Tube assay. J Clin Microbiol 2013;51:3521-3526.
11. Metcalfe JZ, Cattamanchi A, McCulloch CE, Lew JD, Ha NP, Graviss EA. Test variability of the QuantiFERON-TB Gold In-Tube assay in clinical practice. Am J Respir Crit Care Med 2013;187:206-211.
12. Zwerling A, Benedetti A, Cojocariu M, McIntosh F, Pietrangelo F, Behr MA, Schwartzman K, Menzies D, Pai M. Repeat IGRA testing in Canadian health workers: conversions or unexplained variability? PLoS One 2013;8:e54748.
13. Slater ML, Welland G, Pai M, Parsonnet J, Banaei N. Challenges with QuantiFERON-TB Gold assay for large-scale, routine screening of U.S. healthcare workers. Am J Respir Crit Care Med 2013;188:1005-1010.
14. Pai M, Joshi R, Dogra S, Zwerling AA, Gajalakshmi D, Goswami K, Reddy MV, Kalantri A, Hill PC, Menzies D, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 2009;13:84-92.
15. Naseer A, Naqvi S, Kampmann B. Evidence for boosting Mycobacterium tuberculosis-specific IFN-γ responses at 6 weeks following tuberculin skin testing. Eur Respir J 2007;29:1282-1283.
16. Vilaplana C, Ruiz-Manzano J, Gil O, Cuchillo F, Montané E, Singh M, Spallek R, Ausina V, Cardona PJ. The tuberculin skin test increases the responses measured by T cell interferon-γ release assays. Scand J Immunol 2008;67:610-617.
17. Choi JC, Shin JW, Kim JY, Park IW, Choi BW, Lee M-K. The effect of previous tuberculin skin test on the follow-up examination of whole-blood interferon-γ assay in the screening for latent tuberculosis infection. Chest 2008;133:1415-1420.
18. Igari H, Watanabe A, Sato T. Booster phenomenon of QuantiFERON-TB Gold after prior intradermal PPD injection. Int J Tuberc Lung Dis 2007;11:788-791.
19. Sauzullo I, Massetti AP, Mengoni F, Rossi R, Lichtner M, Ajassa C, Vullo V, Mastroianni CM. In fluence of previous tuberculin skin test on serial IFN-γ release assays. Tuberculosis (Edinb) 2011;91:322-326.
20. Ritz N, Yau C, Connell TG, Tebruegge M, Leslie D, Curtis N. Absence of interferon-γ release assay conversion following tuberculin skin testing. Int J Tuberc Lung Dis 2011;15:767-769.
21. Republic of South Africa Department of Health. National tuberculosis management guidelines 2009 [accessed 2015 Jan 19]. Available from: http://familymedicine.ukzn.ac.za/Libraries/Guidelines-Protocols/TB-Guidelines-2009.sflb.ashx.
22. Silverman BW. Using kernel density estimates to investigate multimodality. J R Stat Soc Series B Stat Methodol 1981;43:97-99.
23. Middelkoop K, Bekker L-G, Liang H, Aquino LD, Sebastian E, Myer L, Wood R. Force of tuberculosis infection among adolescents in a high HIV and TB prevalence community: a cross-sectional observation study. BMC Infect Dis 2011;11:156.
24. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177-184.
25. Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P, Wang Y, Cronin W, Hirsch-Moverman Y, Teeter LD, et al.; Tuberculosis Epidemiologic Studies Consortium. Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med 2014;189:77-87.
26. Joshi M, Monson TP, Joshi A, Woods GL. IFN-γ release assay conversions and reversions: challenges with serial testing in U.S. health care workers. Ann Am Thorac Soc 2014;11:296-302.
27. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, Fielding K, Wilkinson RJ, Pai M. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:45-55.
28. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012;142:63-75.
29. Dahlstrom AW. The instability of the tuberculin reaction: observations on dispensary patients with special reference to the existence of demonstrable tuberculous lesions and the degree of exposure to tubercle bacilli. Am Rev Tuberc Pulm Dis 1940;42:471-487.
30. Adams JM, Kalajan VA, Mork BO, Rosenblatt M, Rothrock WJ, O'Loughlin BJ. Reversal of tuberculin reaction in early tuberculosis. Dis Chest 1959;35:348-356.
31. Pai M, O'Brien R. Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions? PLoS Med 2007;4:e208.
32. Hill PC, Brookes RH, Fox A, Jackson-Sillah D, Jeffries DJ, Lugos MD, Donkor SA, Adetifa IM, de Jong BC, Aiken AM, et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med 2007;4:e192.
33. Slater M, Parsonnet J, Banaei N. Investigation of false-positive results given by the QuantiFERON-TB Gold In-Tube assay. J Clin Microbiol 2012;50:3105-3107.
34. Doberne D, Gaur RL, Banaei N. Preanalytical delay reduces sensitivity of QuantiFERON-TB Gold In-Tube assay for detection of latent tuberculosis infection. J Clin Microbiol 2011;49:3061-3064.
35. Shanaube K, De Haas P, Schaap A, Moyo M, Kosloff B, Devendra A, Raby E, Godfrey-Faussett P, Ayles H. Intra-assay reliability and robustness of QuantiFERON ®-TB Gold In-Tube test in Zambia. Int J Tuberc Lung Dis 2010;14:828-833.
36. Whitworth WC, Hamilton LR, Goodwin DJ, Barrera C, West KB, Racster L, Daniels LJ, Chuke SO, Campbell BH, Bohanon J, et al. Within-subject interlaboratory variability of QuantiFERON-TB Gold In-Tube tests. PLoS One 2012;7:e43790.
37. Whitworth WC, Goodwin DJ, Racster L, West KB, Chuke SO, Daniels LJ, Campbell BH, Bohanon J, Jaffar AT, Drane W, et al. Variability of the QuantiFERON®-TB Gold In-Tube test using automated and manual methods. PLoS One 2014;9:e86721.
38. Kritzinger FE, den Boon S, Verver S, Enarson DA, Lombard CJ, Borgdorff MW, Gie RP, Beyers N. No decrease in annual risk of tuberculosis infection in endemic area in Cape Town, South Africa. Trop Med Int Health 2009;14:136-142.
39. Wood R, Liang H, Wu H, Middelkoop K, Oni T, Rangaka MX, Wilkinson RJ, Bekker LG, Lawn SD. Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int J Tuberc Lung Dis 2010;14:406-412.
40. Sutherland I. The effect of tuberculin reversion upon the estimate of the annual risk of infection. Bull Int Union Tuberc 1971;45:115-118.
41. Fine PE, Bruce J, Ponnighaus JM, Nkhosa P, Harawa A, Vynnycky E. Tuberculin sensitivity: conversions and reversions in a rural African population. Int J Tuberc Lung Dis 1999;3:962-975.
42. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG world atlas: a database of global BCG vaccination policies and practices. PLoS Med 2011;8:e1001012.
43. Andrews JR, Morrow C, Walensky RP, Wood R. Integrating social contact and environmental data in evaluating tuberculosis transmission in a South African township. J Infect Dis 2014;210:597-603.